Basit öğe kaydını göster

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

dc.contributor.authorBuyukunal, E.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorTurna, H.
dc.contributor.authorSerdengecti, S.
dc.contributor.authorDemirelli, FUAT HULUSİ
dc.contributor.authorÖztürk, Turgut
dc.contributor.authorIlvan, S.
dc.contributor.authorTural, D.
dc.date.accessioned2021-03-03T07:54:54Z
dc.date.available2021-03-03T07:54:54Z
dc.date.issued2014
dc.identifier.citationTural D., Serdengecti S., Demirelli F. H. , Öztürk T., Ilvan S., Turna H., Ozguroglu M., Buyukunal E., "Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies", BRITISH JOURNAL OF CANCER, cilt.110, sa.8, ss.1968-1976, 2014
dc.identifier.issn0007-0920
dc.identifier.othervv_1032021
dc.identifier.otherav_14968ab4-fa0a-48dc-85f6-ee04cf699cc4
dc.identifier.urihttp://hdl.handle.net/20.500.12627/19231
dc.identifier.urihttps://doi.org/10.1038/bjc.2014.72
dc.description.abstractBackground: Overexpression of p185HER2 is an established poor prognostic factor in breast cancer, portending an aggressive course and potential for early metastasis. On the other hand, monoclonal antibody trastuzumab is widely used in the clinic to target this overexpressed oncogene. Unfortunately, similar to 30-40% of all patients overexpressing HER2 respond to trastuzumab, warranting further research regarding the structure and additional modulation of the receptor. In this study, we aimed to investigate the response to trastuzumab in terms of the potential roles of several oncogenic pathways (phosphatase and tensin homologue (PTEN) and phosphatidylinositol 3-kinase (PI3K)) and a truncated receptor protein, p95HER2, retrospectively.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleClinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
dc.typeMakale
dc.relation.journalBRITISH JOURNAL OF CANCER
dc.contributor.departmentİstanbul Teknik Üniversitesi , İnşaat , İnşaat Mühendisliği
dc.identifier.volume110
dc.identifier.issue8
dc.identifier.startpage1968
dc.identifier.endpage1976
dc.contributor.firstauthorID14515


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster